Endocrine Connections · 2018 · 11 citations · 18 references
MedicineEndocrinologyPediatricsClinical NutritionMetabolic RegulationPediatric EndocrinologyBody CompositionChildhood ObesityInsulin ResistanceWeight LossWeight ManagementLifestyle Exercise InterventionLifestyle Intervention EffectsLifestyle Intervention TrialsLipid Metabolism EffectsMultivariate Linear ModelsPhysiological Weight LossWaist Circumference MeasurementWeight Loss Metabolism
Background: Fibroblast growth factor 1 (FGF1) can regulate glucose and lipid metabolism in obese mice. Serum FGF1 has increased in type 2 diabetes mellitus adults and correlated with BMI. This study aimed to indicate conventional weight loss effects on FGF1 in obese children and adolescents. Materials and Methods: Clinical and metabolic parameters of 88 lean and obese individuals (ages 5–15 years) and 39 obese individuals followed with 6 months of lifestyle intervention were collected. Serum FGF1 levels were detected through enzyme-linked immunosorbent assays. Results: FGF1 levels were increased in obese individuals. Serum FGF1 levels were significantly correlated with BMI and waist circumferences (r = 0.377, P = 0.012; r = 0.301, P = 0.047, respectively). Multivariate stepwise linear regression analyses showed that FGF1 levels were significantly correlated with HbA1c and HOMA-IR (β = 0.371, P = 0.008; β = 0.323, P = 0.021, respectively). Weight loss (2.3 ± 0.1 kg) was accompanied by a significant reduction of circulating FGF1 levels (7.2 ± 0.4 pg/mL). Changes in FGF1 were significantly correlated with changes in fasting glucose, HOMA-IR and low-density lipoprotein cholesterol (β = 0.277, P = 0.020; β = 0.474, P < 0.001; β = 0.320, P = 0.008, respectively). Conclusion: FGF1 levels were increased in obese individuals. Serum FGF1 levels were significantly correlated with BMI and waist circumferences (r = 0.377, P = 0.012; r = 0.301, P = 0.047, respectively). Multivariate stepwise linear regression analyses showed that FGF1 levels were significantly correlated with HbA1c and HOMA-IR (β = 0.371, P = 0.008; β = 0.323, P = 0.021, respectively). Weight loss (2.3 ± 0.1 kg) was accompanied by a significant reduction of circulating FGF1 levels (7.2 ± 0.4 pg/mL). Changes in FGF1 were significantly correlated with changes in fasting glucose, HOMA-IR and low-density lipoprotein cholesterol (β = 0.277, P = 0.020; β = 0.474, P < 0.001; β = 0.320, P = 0.008, respectively).
18
Leandra Abarca-Gómez, Ziad Abdeen, Zargar Abdul Hamid et al. · The Lancet · 2017 · 7.6K citations · Full text
FGF-21 as a novel metabolic regulator
Alexei Kharitonenkov, Tatiyana L. Shiyanova, Anja Köester et al. · Journal of Clinical Investigation · 2005 · 2.1K citations · Full text
Receptor Specificity of the Fibroblast Growth Factor Family
David M. Ornitz, Jennifer S. Colvin, Donald G. McEwen et al. · Journal of Biological Chemistry · 1996 · 1.9K citations · Full text